iqvia semaglutide tirzepatide prescriptions us q3 2024 iqvia glp-1 prescriptions q3 2024 semaglutide tirzepatide Prescriptions Are Up, Health Services Utilization Down, and GLP-1s Are a Major Growth Driver: IQVIA's 2024 Update-bsmoothhr GLP-1 Antagonists Increase Plan Drug
Description
DOI: 10.1136/bmj-2025-085304 Funding: National Institute of Health and Care Research (NIHR) Oxford Biomedical Research Centre Never miss a breakthrough: Join the SciTechDaily newsletter
Some secondary analyses had nominal significance in favor of tirzepatide, with a 16% reduction in all-cause mortality versus dulaglutide (HR 0.84
The median prescription span was 482 days (IQR 161925), corresponding to 15.9 months (IQR 5.330.4 months)
Seek urgent medical attention for chest pain, severe breathlessness, syncope, or irregular heartbeat with symptoms
All require a prescription
Multiple Genes of the Renin-Angiotensin System Are Novel Targets of Wnt/-Catenin Signaling
